RRx-001

Phase 3Small molecule

EEpicentRx, Inc.

RRx-001 is one of 206 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

205

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Ovarian CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

GlioblastomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Oral MucositisActive, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Oral MucositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 3

Perjeta

Roche

Phase 3

3 4

Aromasin

Pfizer

Phase 3

2 5

Taxotere

AAvyxa

Phase 3

11 6

Veliparib

AbbVie

Phase 3

5 7

Taxane

Bristol-Myers Squibb

Phase 3

2 8

RRx-001

EEpicentRx, Inc.

Phase 3

1 9

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 10

Hydralazine and Magnesium Valproate

NNational Institute of Cancerología

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Oral Mucositis

NCT05966194

Clinical

Trials by Indication[1]

Oral Mucositis2 trials

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

Completed·EEpicentRx, Inc.·Phase 2·NCT03515538·53 enrolled

A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Active, not recruiting·EEpicentRx, Inc.·Phase 2·NCT05966194·216 enrolled

Cancer1 trial

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Completed·EEpicentRx, Inc.·Phase 1·NCT01359982·26 enrolled

Nivolumab1 trial

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Completed·EEpicentRx, Inc.·Phase 1·NCT02518958·12 enrolled

Ovarian Cancer1 trial

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Cholangiocarcinoma1 trial

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Terminated·EEpicentRx, Inc.·Phase 2·NCT02452970·4 enrolled

7 more indications

Pilot Study1 trial

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Terminated·EEpicentRx, Inc.·Phase 1·NCT02096341·2 enrolled

Central Nervous System Tumor1 trial

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Terminated·EEpicentRx, Inc.·Phase 1·NCT04525014·2 enrolled

Metastatic Colorectal Cancer1 trial

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Completed·EEpicentRx, Inc.·Phase 2·NCT02096354·62 enrolled

Small Cell Lung Cancer1 trial

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

Active, not recruiting·EEpicentRx, Inc.·Phase 3·NCT05566041·292 enrolled

Whole Brain Radiation1 trial

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

Completed·EEpicentRx, Inc.·Phase 1·NCT02215512·29 enrolled

Glioblastoma1 trial

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

Completed·EEpicentRx, Inc.·Phase 1·NCT02871843·19 enrolled

Advanced Cancer1 trial

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Terminated·EEpicentRx, Inc.·Phase 1·NCT02801097·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for RRx-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RRx-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RRx-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EpicentRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEpicentRx, Inc.

RRx-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Oral Mucositis2 trials

Cancer1 trial

Nivolumab1 trial

Ovarian Cancer1 trial

Cholangiocarcinoma1 trial

Pilot Study1 trial

Central Nervous System Tumor1 trial

Metastatic Colorectal Cancer1 trial

Small Cell Lung Cancer1 trial

Whole Brain Radiation1 trial

Glioblastoma1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News